微創醫療(00853.HK):心脈醫療一季度營收增10.75%至2.86億元
格隆匯4月27日丨微創醫療(00853.HK)公佈,2023年1-3月,公司附屬心脈醫療(688016.SH)實現營業收入為人民幣2.86億元,同比增長10.75%;歸屬於心脈醫療股東的淨利潤人民幣1.25億元,同比增長1.10%;歸屬於心脈醫療股東的扣除非經常性損益的淨利潤人民幣1.20億元,同比增長1.58%,基本每股收益人民幣1.73元。
受整體形勢和春節因素影響,醫院一月份手術量顯着減少,心脈醫療經銷商也未像往年在春節前進行正常備貨,致心脈醫療一月份銷售收入大幅低於去年同期。隨着醫院逐步恢復正常運轉,2 月醫院手術量開始回升,3 月份手術量全面恢復,與之對應心脈醫療5 款創新產品植入量在 3 月份均創月度歷史新高。
2023 年 1-3 月,Castor 分支型主動脈覆膜支架及輸送系統植入量同比增長24.32%,Minos 腹主動脈覆膜支架及輸送系統植入量同比增長 45.51%,Reewarm PTX 藥物球囊擴張導管同比增長 62.54%。研發投入包括費用化及資本化的研發投入。報吿期內心脈醫療繼續加大研發投入,研發投入較去年同期增長 43.51%,佔同期心脈醫療營業收入的比例為 21.3%。
預期年度內完成 13 款在研產品註冊資料遞交,7 款在研產品進入臨牀試驗階段並完成首例臨牀植入。報吿期內心脈醫療繼續發力開拓海外市場,已拓展至 25 個國家,海外銷售收入較去年同期強勁增長 138%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.